



Stoma Product Assessment Panel Public Summary Documents

NicePak – 27 May 2025

Contents

NicePak Sudocrem Healing Cream 100g Tube – NP#01MAY2025	2
---	---



NicePak Sudocrem Healing Cream 100g Tube –

NP#01MAY2025

Proposed Listing on the Stoma Appliance Scheme

The applicant, NicePak, sought listing of NicePak Sudocrem Healing Cream 100g in subgroup 9(f) of the Stoma Appliance Scheme (SAS) Schedule. The product, including one variant, was proposed for listing at a unit price of \$9.500 (annual cost of \$57.000), with a pack size of 1 unit and maximum annual maximum quantity of 6 units.

Comparator

The applicant nominated 3M Cavidol Durable (SAS Code 9858W) as the comparator. The comparator product (one variant) is currently listed in subgroup 9(f) of the SAS Schedule at the unit price of \$5.750 (annual cost of \$69.000), with a pack size of 1 unit and maximum monthly quantity of 1 unit.

Background

This was the Stoma Product Assessment Panel's (the Panel) first consideration of this product.

Clinical Analysis

The proposed product would provide an alternative for users requiring a barrier cream. The Panel noted that NicePak did not provide evidence to establish that the current maximum quantity is insufficient. The evidence NicePak provided relates to general skin care and is not specific to the management of a stoma. The Panel noted that there is no clinical need for the increase size, and the amount would be excessive and could result in unnecessary increased usage by ostomates.

Economic and Financial Analysis

The Panel noted the product was proposed for listing at the same price and the same maximum monthly quantity as currently listed products in the same subgroup. If the product were recommended for listing in the future, it would be expected to result in the same cost to the SAS.

Panel Recommendation

The Panel rejected the application for NicePak Sudocrem Healing Cream 100g to be listed in subgroup 9(f) of the SAS Schedule with one variant, at the unit price of \$9.500, with a pack size of 1 unit and maximum monthly quantity of 1 unit, noting there is no clinical need for the increased size of the product.



The Panel noted the product is currently available on the SAS Schedule in a smaller quantity which is clinically appropriate and NicePak's application did not provide sufficient evidence to support why the increased quantity is clinically necessary. Ostomates can seek additional supplies of the product through usual SAS processes if a larger quantity is required.

Context for Recommendation

The Panel provides advice on whether stoma products should be subsidised and, if so, the conditions of their subsidy in Australia. Applications are considered in this context. Panel advice not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. An applicant can resubmit to the Panel following advice not to recommend listing or changes to a listing.

Applicant's Comment

The applicant noted the recommendation.